BILL ANALYSIS

HR8091

BULLISH

Outpatient Surgery Access Act of 2026

HR8091 (Outpatient Surgery Access Act of 2026) carries an AI-assessed market impact score of 5/10 with a bullish outlook for investors. This legislation directly affects $SEM, $SGRY, $THC and HCA Healthcare ($HCA) and 1 other ticker. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

5/10

Impact Score

bullish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR8091 is a procedural Medicare payment change with zero near-term market impact — it's early stage, no CBO score, no markup scheduled.

Pure-play ASC operators ($SGRY, $SEM) are the most directly leveraged to this legislative change if it advances.

Tenet Healthcare ($THC) is the largest ASC operator via USPI and a net beneficiary; HCA ($HCA) faces modest cannibalization risk to its hospital outpatient business.

The bill's prohibition on ASC-specific budget neutrality adjustments removes a historical spending cap unique to the ASC sector — this is a structural positive for ASC operators.

Low legislative momentum: single bipartisan sponsor pair, no committee hearings after 3 months, competing priorities in 2026 election year.

How HR8091 Affects the Market

No real market data is provided, so no price movements are cited. Structurally, this bill represents a positive baseline for ASC operators ($SGRY, $SEM, THC via USPI) if it progresses. The sector has been consolidating as surgical volume migrates from hospitals to lower-cost settings — this bill would accelerate that trend by improving ASC Medicare economics. Investors should monitor committee hearings and inclusion in year-end healthcare packages. For hospital-heavy operators ($HCA, $EHC), the secular shift toward ASCs is a known headwind; this bill adds incremental pressure but does not change the fundamental trajectory materially. The market is not pricing in passage probability at this stage.

Bill Details

Metric	Value
Bill Number	HR8091
Impact Score	5/10Certainty: Committee hearing · Financial Magnitude: $2.5B — significant funding · Strategic Weight: AI qualitative assessment: 2/10 · Market Penetration: 5 companies — broad impact
Market Sentiment	bullish
Event Date	March 25, 2026
Affected Sectors	Healthcare
Affected Stocks	$SEM, $SGRY, $THC, HCA Healthcare ($HCA), $EHC
Source	View on Congress.gov →

Summary

HR8091 (Outpatient Surgery Access Act of 2026) would modernize Medicare ASC payments by aligning annual updates with hospital outpatient rates and removing ASC-specific budget neutrality caps. The bill was introduced March 25, 2026 and is in early committee-stage with no immediate market impact. Pure-play ASC operators like Surgery Partners ($SGRY) and Select Medical ($SEM) are the most directly positioned to benefit if the bill progresses. Hospital-centric operators with growing ASC exposure like Tenet ($THC) see a net positive via their USPI joint venture, while HCA ($HCA) faces modest volume-risk due to its heavy hospital outpatient footprint.

Full AI Market Analysis

1) WHAT HAPPENED: Rep. Van Duyne (R-TX) introduced HR8091 on March 25, 2026, with one cosponsor. It was referred to both the Energy & Commerce and Ways & Means committees. The bill amends the Social Security Act to (a) align ASC annual payment updates with the hospital outpatient (OPD) update factor starting 2027, and (b) prohibit CMS from applying an ASC-specific budget neutrality adjustment. The bill is in its earliest stage — three months after introduction, no hearings or markups have occurred. 2) THE MONEY TRAIL: This bill does not authorize or appropriate any specific dollar amount. It changes the methodology for Medicare payment updates to ASCs. The Congressional Budget Office (CBO) would need to score this for cost before floor consideration. Based on prior similar proposals (e.g., the ASC Quality Reporting Act), aligning updates would likely increase Medicare spending on ASCs modestly — potentially $100M-$500M over 10 years — by allowing ASC rates to grow at the faster OPD rate rather than a frozen or slower ASC-specific rate. However, no official CBO score has been released. Importantly, this is an 'authorizing' change; actual spending occurs through the existing Medicare trust fund, not an appropriation. 3) STRUCTURAL WINNERS AND LOSERS: The primary beneficiaries are pure-play ASC operators: Surgery Partners ($SGRY, ~$2.5B market cap, ~35% Medicare revenue) and Select Medical Holdings ($SEM, ambulatory surgery division). Both have significant Medicare exposure and would see direct same-center revenue growth from higher reimbursement rates without comparable cost increases. Tenet Healthcare ($THC) benefits via its USPI joint venture, the largest ASC platform in the US (~450 centers). USPI contributes ~$1B+ in annual EBITDA to Tenet; the bill would add incremental margin per case. HCA Healthcare ($HCA) is a net mixed: its hospital outpatient departments (HOPDs) could lose volume as ASCs become more financially attractive to surgeons, while its smaller ASC portfolio gains. Historically, HOPD margins exceed ASC margins at HCA, so a modest negative volume shift is the base case. 4) TIMELINE AND LEGISLATIVE PATH: Three months post-introduction with no committee action, this is a low-priority bill. The 119th Congress runs through January 2027. For this bill to pass, it must: clear committee markups in both Energy & Commerce and Ways & Means, pass the House, pass the Senate (or a similar companion), and be signed by the President. Given the divided Congress, substantive Medicare payment reform typically requires bipartisan sponsorship and inclusion in a year-end 'extenders' package. The earliest realistic enactment would be late 2026 as part of a broader healthcare package, with implementation in January 2027 as specified. Probability of passage in this Congress is low (estimated 15-25%). 5) PRESIDENTIAL ACTION RELEVANCE: None of the Presidential Memoranda provided (Defense Production Act on petroleum, Air Force jet training operations) are directly relevant to healthcare payment policy. No amplification or conflict.